Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting

Autor:	Adnan Tufail, Marko Lukic, Philip G Hykin, Sobha Sivaprasad, Maria Eleftheriadou, Praveen J Patel, Ranjan Rajendram, Maria K Gemenetzi, Robin Hamilton
Rok vydání:	2018
Předmět:	medicine.medical_specialty genetic structures Treatment outcome Spectral domain AMD 03 medical and health sciences 0302 clinical medicine Ophthalmology Age related medicine Routine clinical practice 030212 general & internal medicine Clinical settings Aflibercept Original Research business.industry Anti-VEGF Diabetic retinopathy Macular degeneration medicine.disease Functional Treatment Real-life outcomes 030221 ophthalmology & optometry business medicine.drug
Zdroj:	Ophthalmology and Therapy
ISSN:	2193-8245
Popis:	Introduction To report 3-year treatment outcomes with intravitreal aflibercept injections for neovascular age-related macular degeneration (nAMD) in routine clinical practice. Methods This was a retrospective, single-centre, non-randomized interventional case series analysis. Data from treatment-naïve patients with nAMD treated between 1 October 2013 and 31 February 2014 were included in the analysis. Data including age, gender, vision acuity (VA) measured on Early Treatment of Diabetic Retinopathy Study charts (ETDRS) and injection numbers were recorded. Spectral domain optical coherence tomography (SD-OCT) data including presence or absence of macular fluid and automated central subfield macular thickness (CSMT) at year 1, 2 and 3 were also recorded. Results Of the 157 eyes of 148 patients treated, data from 108 eyes of 102 patients were available at 3-year follow-up. The mean (± SD) age was 80.6 ± 8.3 years with a mean of 154.5 ± 5.4 weeks follow-up. The mean VA changed from 54.4 ± 16 letters at baseline to 60.3 ± 18.1 letters (VA gain 5.9 ± 13.8 letter gain) at 1 year, to 60.8 ± 17.4 letters (VA gain 6.4 ± 14.9 letters) at 2 years and to 61.0 ± 16.6 letters (VA gain 6.6 ± 15.4 letters) at 3 years. The reduction in CSMT was 77.9 ± 101.4 µm with absence of macular fluid in 71% of eyes. The total mean number of injections was 15.9 ± 6.1 at year 3. Conclusion The results suggest that good long-term morphological and functional treatment outcomes can be achieved using aflibercept for nAMD in a clinical setting. Electronic supplementary material The online version of this article (10.1007/s40123-018-0139-5) contains supplementary material, which is available to authorized users.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d1fd9b9144167a3dfec407231bdeef0 https://pubmed.ncbi.nlm.nih.gov/29982914 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.